Longitudinal Analysis of CD8+ T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2004 May 14

PMID 15140968

Citations 149

Authors

George J M Webster

Stephanie Reignat

David Brown

Graham S Ogg

Louise Jones

Suranjith L Seneviratne

Roger Williams

Geoffrey Dusheiko

Antonio Bertoletti

Affiliations

Soon will be listed here.

Abstract

The cytotoxic T-cell response in chronic hepatitis B virus (HBV) infection has been described as weak and mono- or oligospecific in comparison to the more robust virus-specific T-cell response present in resolved infection. However, chronic hepatitis B is a heterogeneous disease with markedly variable levels of virus replication and liver disease activity. Here we analyzed (both directly ex vivo and after in vitro stimulation) the HBV-specific CD8 T-cell responses against structural and nonstructural HBV proteins longitudinally in patients with different patterns of chronic infections. We found that the profiles of virus-specific CD8(+)-T-cell responses during chronic infections are highly heterogeneous and influenced more by the level of HBV replication than by the activity of liver disease. An HBV DNA load of <10(7) copies/ml appears to be the threshold below which circulating multispecific HBV-specific CD8(+) T cells are consistently detected. Furthermore, CD8(+) T cells with different specificities are differentially regulated during chronic infections. HBV core-specific CD8(+) T cells are associated with viral control, while CD8(+) T cells specific for envelope and polymerase epitopes can occasionally be found in the setting of high levels (>10(7) copies) of HBV replication. These findings have implications for the design of immunotherapy for chronic HBV infections.

Citing Articles

Obtaining HBV core protein VLPs carrying SARS-CoV-2 nucleocapsid conserved fragments as vaccine candidates.

Lobaina Y, Musacchio A, Ai P, Chen R, Suzarte E, Chinea G Virol J. 2024; 21(1):310.

PMID: 39609857 PMC: 11606075. DOI: 10.1186/s12985-024-02583-9.

Optimization of culture conditions for HBV-specific T cell expansion in vitro from chronically infected patients.

Wang L, Chen H, Yang Y, Huang Y, Chen W, Mu D BMC Biotechnol. 2024; 24(1):80.

PMID: 39402512 PMC: 11476462. DOI: 10.1186/s12896-024-00908-8.

Attenuated effector T cells are linked to control of chronic HBV infection.

Heim K, Sagar , Sogukpinar O, Llewellyn-Lacey S, Price D, Emmerich F Nat Immunol. 2024; 25(9):1650-1662.

PMID: 39198634 PMC: 11362014. DOI: 10.1038/s41590-024-01928-4.

Peptide-Loaded HLA Class I Tetramer-Associated Magnetic Bead-Based Enrichment of HBV-Specific CD8+ T Cells.

Heim K, Hofmann M, Thimme R Methods Mol Biol. 2024; 2837:219-226.

PMID: 39044088 DOI: 10.1007/978-1-0716-4027-2_19.

Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8 T cell quality.

Takahama S, Yoshio S, Masuta Y, Murakami H, Sakamori R, Kaneko S Front Immunol. 2023; 14:1257113.

PMID: 37920475 PMC: 10619684. DOI: 10.3389/fimmu.2023.1257113.

References

Penna A, Del Prete G, Cavalli A, Bertoletti A, DElios M, Sorrentino R . Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology. 1997; 25(4):1022-7. DOI: 10.1002/hep.510250438. View

Chisari F . Cytotoxic T cells and viral hepatitis. J Clin Invest. 1997; 99(7):1472-7. PMC: 507965. DOI: 10.1172/JCI119308. View

Bertoni R, Sidney J, Fowler P, Chesnut R, Chisari F, Sette A . Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest. 1997; 100(3):503-13. PMC: 508216. DOI: 10.1172/JCI119559. View

Bocher W, Herzog-Hauff S, Schlaak J, Meyer zum Buschenfeld K, Lohr H . Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology. 1998; 29(1):238-44. DOI: 10.1002/hep.510290120. View

Morgan D, Kreuwel H, Sherman L . Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol. 1999; 163(2):723-7. View

Jung M, Hartmann B, Gerlach J, Diepolder H, Gruber R, Schraut W . Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology. 1999; 261(2):165-72. DOI: 10.1006/viro.1999.9833. View

Maini M, Boni C, Ogg G, King A, Reignat S, Lee C . Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology. 1999; 117(6):1386-96. DOI: 10.1016/s0016-5085(99)70289-1. View

Chen W, Anton L, Bennink J, Yewdell J . Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity. 2000; 12(1):83-93. DOI: 10.1016/s1074-7613(00)80161-2. View

Maini M, Boni C, Lee C, Larrubia J, Reignat S, Ogg G . The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000; 191(8):1269-80. PMC: 2193131. DOI: 10.1084/jem.191.8.1269. View

10.

Webster G, Reignat S, Maini M, Whalley S, Ogg G, King A . Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology. 2000; 32(5):1117-24. DOI: 10.1053/jhep.2000.19324. View

11.

Sing G, Ladhams A, Arnold S, Parmar H, Chen X, Cooper J . A longitudinal analysis of cytotoxic T lymphocyte precursor frequencies to the hepatitis B virus in chronically infected patients. J Viral Hepat. 2001; 8(1):19-29. DOI: 10.1046/j.1365-2893.2001.00260.x. View

12.

Perrillo R . Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001; 120(4):1009-22. DOI: 10.1053/gast.2001.22461. View

13.

Boni C, Penna A, Ogg G, Bertoletti A, Pilli M, Cavallo C . Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology. 2001; 33(4):963-71. DOI: 10.1053/jhep.2001.23045. View

14.

Sobao Y, Sugi K, Tomiyama H, Saito S, Fujiyama S, Morimoto M . Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia. J Hepatol. 2001; 34(6):922-9. DOI: 10.1016/s0168-8278(01)00048-4. View

15.

Lok A, McMahon B . Chronic hepatitis B. Hepatology. 2001; 34(6):1225-41. DOI: 10.1053/jhep.2001.29401. View

16.

Sobao Y, Tomiyama H, Sugi K, Tokunaga M, Ueno T, Saito S . The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol. 2002; 36(1):105-15. DOI: 10.1016/s0168-8278(01)00264-1. View

17.

Lau G, Suri D, Liang R, Rigopoulou E, Thomas M, Mullerova I . Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology. 2002; 122(3):614-24. DOI: 10.1053/gast.2002.31887. View

18.

Reignat S, Webster G, Brown D, Ogg G, King A, Seneviratne S . Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med. 2002; 195(9):1089-101. PMC: 2193712. DOI: 10.1084/jem.20011723. View

19.

Lauer G, Ouchi K, Chung R, Nguyen T, Day C, Purkis D . Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol. 2002; 76(12):6104-13. PMC: 136241. DOI: 10.1128/jvi.76.12.6104-6113.2002. View

20.

Brehm M, Pinto A, Daniels K, Schneck J, Welsh R, Selin L . T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol. 2002; 3(7):627-34. DOI: 10.1038/ni806. View